BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 17564876)

  • 1. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
    Gibson AE; Degenhardt LJ
    Drug Alcohol Rev; 2007 Jul; 26(4):405-10. PubMed ID: 17564876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
    Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
    Bell J; Trinh L; Butler B; Randall D; Rubin G
    Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid-dependent error processing.
    Fellows-Smith J
    J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing overdose mortality associated with methadone and buprenorphine treatment.
    Bell JR; Butler B; Lawrance A; Batey R; Salmelainen P
    Drug Alcohol Depend; 2009 Sep; 104(1-2):73-7. PubMed ID: 19443138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable mortality profile of naltrexone implants for opiate addiction.
    Reece AS
    J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
    Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
    Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
    Anchersen K; Clausen T; Gossop M; Hansteen V; Waal H
    Addiction; 2009 Jun; 104(6):993-9. PubMed ID: 19392907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
    Tait RJ; Ngo HT; Hulse GK
    J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004.
    Morgan O; Griffiths C; Hickman M
    Int J Epidemiol; 2006 Dec; 35(6):1579-85. PubMed ID: 17077102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series.
    Kakko J; Heilig M; Sarman I
    Drug Alcohol Depend; 2008 Jul; 96(1-2):69-78. PubMed ID: 18355989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
    Nielsen S; Dietze P; Lee N; Dunlop A; Taylor D
    Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
    Ngo HT; Tait RJ; Hulse GK
    Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.
    Kelty E; Hulse G; Joyce D; Preen DB
    CNS Drugs; 2020 Jun; 34(6):629-642. PubMed ID: 32215842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
    Kelty E; Hulse G
    Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-related mortality and filled prescriptions for buprenorphine and methadone.
    Wikner BN; Öhman I; Seldén T; Druid H; Brandt L; Kieler H
    Drug Alcohol Rev; 2014 Sep; 33(5):491-8. PubMed ID: 24735085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.